Lista de obras - Rodger Tiedemann - Dominio Público Uruguay

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin.

artículo científico publicado en 2007

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

artículo científico publicado en 2017

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

artículo científico publicado en 2008

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant

artículo científico publicado en 2015

Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience

scientific article published on 20 December 2018

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

artículo científico publicado en 2013

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

artículo científico publicado en 2014

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

scientific article published on 15 June 2013

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma

scientific article published on 17 September 2019

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults.

artículo científico

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

CyBorD induction therapy in clinical practice

artículo científico publicado en 2015

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

artículo científico publicado en 2016

Cyproheptadine displays preclinical activity in myeloma and leukemia

artículo científico publicado en 2008

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents

scientific article published on 27 October 2014

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

artículo científico publicado en 2014

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

artículo científico publicado en 2013

Getting to the root of the problem: the causes of relapse in multiple myeloma

scientific article published on 08 January 2014

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome ⬇️

artículo científico publicado el 6 de diciembre de 2011

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo

artículo científico publicado en 2008

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

artículo científico publicado en 2008

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

artículo científico publicado en 2009

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

artículo científico publicado en 2013

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

artículo científico publicado en 2014

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

scientific article published on 27 November 2019

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2014

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.

artículo científico

On the molecular basis of bacterial superantigen activity

1996 doctoral thesis by Rodger E. Tiedemann at University of Auckland

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

artículo científico publicado en 2010

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

artículo científico publicado en 2019

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

artículo científico publicado en 2007

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5 ⬇️

artículo científico publicado el 2 de febrero de 2011

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients

artículo científico publicado en 2016

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation

artículo científico publicado en 2018

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site

scientific article published on 29 April 2014

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

artículo científico publicado en 2019

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

artículo científico publicado en 2015

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma

artículo científico publicado en 2013

Lista de obras de Rodger Tiedemann

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin.

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant

Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

CyBorD induction therapy in clinical practice

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Cyproheptadine displays preclinical activity in myeloma and leukemia

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Getting to the root of the problem: the causes of relapse in multiple myeloma

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome ⬇️

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.

On the molecular basis of bacterial superantigen activity

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5 ⬇️

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma